Prognostic Signatures Associated with TP53 mutations in chromophobe renal cell carcinoma
IKCS-NA 2025
Nathan Maulding, Andrew Sedgewick, Elizabeth Ellis, Niki Zacharias, Justin Guinney, Pavlos Msaouel
Background
In chromophobe renal cell carcinoma (chRCC), TP53 mutations correlate with advanced disease and chromosomal instability, but the downstream gene expression programs and potential therapeutic vulnerabilities remain unclear.
Methods
We analyzed de-identified clinical data, targeted DNA sequencing, and bulk RNA-seq from 168 chRCC specimens and 226,734 tumors across 25 additional cancer cohorts in the Tempus database. Because chromosomal instability (CIN) is a hallmark consequence of TP53 loss, we applied the 67-gene CINSARC signature, originally developed to quantify CIN risk across solid tumors, to determine whether TP53 status predicts global CIN activity in chRCC. TRIP13, a spindle-checkpoint ATPase included in CINSARC and repeatedly implicated in CIN tolerance, was pre-specified for individual analysis as a tractable, mechanistically relevant candidate target. To evaluate pathway activity, we used GSEA to calculate normalized enrichment scores (NES) between groups.
Results
Tumors with TP53 mutations had significantly higher expression of TRIP13 (p < 1 × 10⁻¹⁰), and enriched CINSARC pathway activity. Other pathways enriched for TP53MUT included G2-M Checkpoint (NES = 2.26, FDR < 0.001), E2F Targets (NES = 2.16, FDR < 0.001) and Mitotic Spindle (NES = 2.10, FDR < 0.001). TRIP13 was highly correlated with mean CINSARC expression (r=0.92, p < 1e-65), and both markers showed strong association with Stage 4 tumors (p < 1 × 10⁻3) and distant metastases (p < 1 × 10⁻4). Other cancer types also showed association between TP53MUT and TRIP13 or CINSARC including Thyroid, Liver, Soft tissue sarcoma, and Breast (p < 1 × 10-50).
Conclusions
CINSARC effectively captures the TP53-dependent CIN phenotype in chRCC, and TRIP13 emerges as its dominant, potentially targetable effector. Together, TRIP13 and CINSARC serve as progression biomarkers and nominate TRIP13 inhibition as a rational therapeutic strategy that merits further investigation for advanced chRCC and other p53-deficient malignancies.
Related publications